The cutting-edge company Velsera, which is focused on developing precision medicine using computational biology, is pleased to publicly announce the appointment of Jamie Littlejohns as its Chief Executive Officer, effective March 1, 2024. Hans Cobben, who has been acting as the CEO in an acting capacity and will return to his role as Chairman of the Board at Velsera, will be replaced by Jamie.
Jamie comes to Velsera from McKinsey, where he oversaw the firm’s European Healthcare & Life Science Private Equity Practice and served as a Partner. Since 2010, he has worked in the healthcare and life sciences sectors in Europe, the US, and Australia. He has honed his skills in assisting investor-backed health and life science tech startups as they grow. Despite being new to Velsera on a full-time basis, Jamie has contributed to the company’s development since the beginning of 2022 by serving as an external advisor.
Jamie states, He was thrilled to be joining the wonderful team at Velsera, in his own words. He is convinced that Velsera’s special blend of skills and abilities will revolutionize precision medicine by quickening the rate of drug development, expanding access to cutting-edge treatments and diagnostics, and enabling more accurate and thorough decision-making on patient care. He was thrilled to collaborate with our customers to create important advancements in the field of precision medicine, and he looked forward to assisting Velsera on the next stage of their growth path.
In addition, the board expressed its approval of Jamie’s hiring through Hans Cobben, the chairman, who said that they are thrilled that Jamie has decided to join Velsera as our incoming CEO. He has a wealth of expertise from working with similar businesses to help them reach their full potential and quicken their growth paths. Moreover, his past involvement with both Summa and Velsera allows him to jump right in, bringing continuity and his own vitality to Velsera. He looks forward to our future growth and prosperity.
The goal of Velsera is to serve as the clinical delivery, evidence generating, and discovery platform for precision medicine. We assist medical professionals and medication seekers in making more informed choices about when and how best to treat patients. After Seven Bridges, PierianDx, and UgenTec merged in 2022, Velsera was established and now operates in the US, Europe, and Asia.
